Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Relapsing Multiple Sclerosis
Clinical trial register · United States · industry-sponsored

Relapsing Multiple Sclerosis Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 01 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 12 Florida 11 Arizona 9 Alabama 7 Colorado 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
TG Therapeutics, Inc.4 Novartis Pharmaceuticals4 Hoffmann-La Roche3 Sanofi1 Sandoz1
State
California12 Florida11 Arizona9 Alabama7 Colorado7
All 24 states
Target enrolment
to

Relapsing Multiple Sclerosis trials in the USA

14 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
TG Therapeutics, Inc.
Phase 2/3
240
Utah
2026-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Active, closed
Sandoz
Phase 3
183
Florida
2025-06-10
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Recruiting
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Active, closed
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Recruiting
TG Therapeutics, Inc.
Phase 3
800
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-06-13
Active, closed
Hoffmann-La Roche
Phase 2
109
California, Nevada
2022-03-01
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Illinois
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2021-12-13
Active, closed
Hoffmann-La Roche
Phase 3
751
Alabama, Arizona, California, District of Columbia, Florida, Indiana, Kansas, Massachusetts
2021-03-24
Active, closed
Hoffmann-La Roche
Phase 3
746
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Louisiana
2021-03-17
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/relapsing-multiple-sclerosis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 01 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Relapsing Multiple Sclerosis.

How many Relapsing Multiple Sclerosis trials are recruiting in the US?

4 of the 14 studies on this page are recruiting new participants as of the 01 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Relapsing Multiple Sclerosis), 14 studies
PhaseStudiesRecruitingShare
Phase 39264.3%
Observational2114.3%
Phase 22014.3%
Phase 2/3117.1%

Most active sponsors

Lead sponsors with the most studies (Relapsing Multiple Sclerosis)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals41
TG Therapeutics, Inc.43
Hoffmann-La Roche30
Sandoz10
Sanofi10
Zenas BioPharma (USA), LLC10

Top states

Top states (Relapsing Multiple Sclerosis), by number of studies with a site there
StateStudies
California12
Florida11
Arizona9
Alabama7
Colorado7
District of Columbia7
Georgia5
Illinois5
Indiana4
Massachusetts4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.